Cytokines Induce Upregulation of Vascular P2Y 2 Receptors and Increased Mitogenic Responses to UTP and ATP
- 1 September 2000
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (9) , 2064-2069
- https://doi.org/10.1161/01.atv.20.9.2064
Abstract
—P2Y 2 receptors, which mediate contractile and mitogenic effects of extracellular nucleotides in vascular smooth muscle cells (VSMCs), are upregulated in the synthetic phenotype of VSMCs and in the neointima after balloon angioplasty, suggesting a role in the development of atherosclerosis. Because released cytokines in atherosclerotic lesions mediate multiple effects on gene transcription in VSMCs, we speculated that cytokines could be involved in the regulation of P2Y 2 receptor expression. Using a competitive reverse transcription–polymerase chain reaction, we detected that interleukin (IL)-1β induced a time- and dose-dependent upregulation of P2Y 2 receptor mRNA, which was dramatically enhanced when combined with interferon-γ or tumor necrosis factor-α. Lipopolysaccharide also significantly increased the expression of P2Y 2 receptor mRNA. The upregulation of P2Y 2 receptor mRNA was paralleled at the functional level because IL-1β significantly increased the UTP-stimulated DNA synthesis and the release of intracellular Ca 2+ . Actinomycin D completely blocked the upregulation of P2Y 2 receptor mRNA expression by IL-1β, indicating de novo mRNA synthesis. There was no cAMP accumulation in the cells stimulated with IL-1β. The cyclooxygenase inhibitor indomethacin and the protein kinase C inhibitor RO-31-8220 inhibited IL-1β–induced upregulation of P2Y 2 receptor mRNA expression, whereas rapamycin and PD098059 had no effects. Furthermore, neither P38 mitogen-activated protein kinase inhibitor SB20358 alone nor its combination with PD098059 blocked the effect of IL-1β on the expression of P2Y 2 receptor mRNA. Our results demonstrate that inflammatory mediators upregulate vascular P2Y 2 receptors at the transcriptional and at the functional level through protein kinase C and cyclooxygenase but not cAMP, extracellular signal–regulated kinases 1 and 2, or P38-dependent pathways. This may result in increased growth-stimulatory or contractile effects of extracellular UTP and ATP, which may be of importance in the development of vascular disease.Keywords
This publication has 44 references indexed in Scilit:
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1Published by Wiley ,2000
- MAPKK-Dependent Growth Factor-Induced Upregulation of P2Y2Receptors in Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 1999
- Extracellular ATPGeneral Pharmacology: The Vascular System, 1998
- Phenotype Changes of the Vascular Smooth Muscle Cell Regulate P2 Receptor Expression as Measured by Quantitative RT-PCRBiochemical and Biophysical Research Communications, 1998
- Differential Roles of Extracellular Signal-regulated Kinase-1/2 and p38MAPK in Interleukin-1β- and Tumor Necrosis Factor-α-induced Low Density Lipoprotein Receptor Expression in HepG2 CellsPublished by Elsevier ,1998
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- P2UPurinergic Activation Leads to the Cell Cycle Progression from the G1to the S and M Phases but Not from the G0to G1Phase in Vascular Smooth Muscle Cells in Primary CultureBiochemical and Biophysical Research Communications, 1996
- Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cellsJournal of Cellular Physiology, 1992